AU2019291307B2 - Combination of LIF inhibitors and platinum-based antineoplastic agents for use in treating cancer - Google Patents

Combination of LIF inhibitors and platinum-based antineoplastic agents for use in treating cancer Download PDF

Info

Publication number
AU2019291307B2
AU2019291307B2 AU2019291307A AU2019291307A AU2019291307B2 AU 2019291307 B2 AU2019291307 B2 AU 2019291307B2 AU 2019291307 A AU2019291307 A AU 2019291307A AU 2019291307 A AU2019291307 A AU 2019291307A AU 2019291307 B2 AU2019291307 B2 AU 2019291307B2
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
seq
lif
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019291307A
Other languages
English (en)
Other versions
AU2019291307A1 (en
Inventor
Judit Anido Folgueira
Patricia Anne Giblin
Robin Matthew Hallett
Jeanne Magram
Naimish PANDYA
Joan Seoane Suarez
Angus SINCLAIR
Robert Wasserman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
MedImmune Ltd
Original Assignee
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron, MedImmune Ltd filed Critical Institucio Catalana de Recerca i Estudis Avancats ICREA
Publication of AU2019291307A1 publication Critical patent/AU2019291307A1/en
Application granted granted Critical
Publication of AU2019291307B2 publication Critical patent/AU2019291307B2/en
Priority to AU2024204564A priority Critical patent/AU2024204564A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019291307A 2018-06-18 2019-06-17 Combination of LIF inhibitors and platinum-based antineoplastic agents for use in treating cancer Active AU2019291307B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024204564A AU2024204564A1 (en) 2018-06-18 2024-07-01 Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382432 2018-06-18
EP18382432.5 2018-06-18
PCT/IB2019/000812 WO2019243900A2 (en) 2018-06-18 2019-06-17 Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024204564A Division AU2024204564A1 (en) 2018-06-18 2024-07-01 Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer

Publications (2)

Publication Number Publication Date
AU2019291307A1 AU2019291307A1 (en) 2021-02-04
AU2019291307B2 true AU2019291307B2 (en) 2024-04-04

Family

ID=62837845

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019291307A Active AU2019291307B2 (en) 2018-06-18 2019-06-17 Combination of LIF inhibitors and platinum-based antineoplastic agents for use in treating cancer
AU2024204564A Pending AU2024204564A1 (en) 2018-06-18 2024-07-01 Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024204564A Pending AU2024204564A1 (en) 2018-06-18 2024-07-01 Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer

Country Status (12)

Country Link
US (1) US20210187106A1 (enExample)
EP (1) EP3806899A2 (enExample)
JP (2) JP7379390B2 (enExample)
KR (1) KR20210022065A (enExample)
CN (1) CN112955178B (enExample)
AU (2) AU2019291307B2 (enExample)
CA (1) CA3103369A1 (enExample)
EA (1) EA202092964A1 (enExample)
IL (1) IL279444A (enExample)
MA (1) MA52300A (enExample)
SG (1) SG11202012576QA (enExample)
WO (1) WO2019243900A2 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011124566A1 (en) * 2010-04-05 2011-10-13 Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron (Vhio) Antibody recognizing human leukemia inhibitory factor (lif) and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation
WO2016040657A1 (en) * 2014-09-10 2016-03-17 The Regents Of The University Of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
WO2019220204A2 (en) * 2018-05-14 2019-11-21 Mosaic Biomedicals Slu Antibodies against lif and dosage forms thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP3283886B1 (en) * 2015-04-17 2020-01-15 Eisai Inc. Methods for treating lung cancer
WO2018115960A1 (en) * 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011124566A1 (en) * 2010-04-05 2011-10-13 Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron (Vhio) Antibody recognizing human leukemia inhibitory factor (lif) and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation
WO2016040657A1 (en) * 2014-09-10 2016-03-17 The Regents Of The University Of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
WO2019220204A2 (en) * 2018-05-14 2019-11-21 Mosaic Biomedicals Slu Antibodies against lif and dosage forms thereof

Also Published As

Publication number Publication date
AU2024204564A1 (en) 2024-07-18
KR20210022065A (ko) 2021-03-02
AU2019291307A1 (en) 2021-02-04
WO2019243900A2 (en) 2019-12-26
EP3806899A2 (en) 2021-04-21
JP2024023212A (ja) 2024-02-21
JP2021533084A (ja) 2021-12-02
JP7603772B2 (ja) 2024-12-20
CA3103369A1 (en) 2019-12-26
IL279444A (en) 2021-01-31
MA52300A (fr) 2021-04-21
WO2019243900A3 (en) 2020-03-05
CN112955178A (zh) 2021-06-11
EA202092964A1 (ru) 2021-03-30
US20210187106A1 (en) 2021-06-24
SG11202012576QA (en) 2021-01-28
CN112955178B (zh) 2025-03-11
JP7379390B2 (ja) 2023-11-14

Similar Documents

Publication Publication Date Title
US10583191B2 (en) Antibodies against LIF and uses thereof
US20230042095A1 (en) Antibodies against lif and uses thereof
AU2019269131B2 (en) Antibodies against LIF and dosage forms thereof
AU2019291307B2 (en) Combination of LIF inhibitors and platinum-based antineoplastic agents for use in treating cancer
HK40107591A (en) Antibodies against lif and uses thereof
HK40016422A (en) Antibodies against lif and uses thereof
HK40016422B (en) Antibodies against lif and uses thereof
EA045781B1 (ru) Антитела к lif и их применения
BR122024020696A2 (pt) Anticorpo recombinante que se liga ao fator inibidor de leucemia e composição farmacêutica compreendendo o referido anticorpo
HK40040276B (zh) 抗lif抗体及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)